Incontinence News and Research

Latest Incontinence News and Research

New report identifies top research priorities related to Female Pelvic Medicine, Reconstructive Surgery

A set of consensus recommendations identifying top research priorities related to female pelvic floor disorders is presented in the January/February issue of Female Pelvic Medicine & Reconstructive Surgery, official journal of The American Urogynecologic Society.

4 Feb 2011

Invacare 2010 adjusted earnings per share increase 16% to $1.84

Invacare Corporation today announced its financial results for the quarter and year ended December 31, 2010 and provided guidance for 2011.

3 Feb 2011

Metamark announces Nature journal published landmark prostate cancer study results

Metamark Genetics, Inc., a privately-held oncology molecular diagnostics company, today announced results from a landmark prostate cancer study published as an Advance Online Publication in the journal Nature.

3 Feb 2011

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.

3 Feb 2011

Public services supporting California's low-income, disabled elderly is fragile, says study

The network of public services that supports California's low-income, disabled elderly is fragile, affecting the ability of these vulnerable residents to live independent lives in their own homes, according to a new study from the UCLA Center for Health Policy Research.

1 Feb 2011

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator.

1 Feb 2011

AMS introduces STEP toolkit to help men with ED and SUI

American Medical Systems, a leading provider of world-class devices and therapies for male and female pelvic health, today announced the launch of its Solutions to Educate Patients Program in Europe.

18 Jan 2011

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

It remains an unresolved issue as to whether interstitial brachytherapy has advantages compared to other therapy options in men with localized prostate cancer, nor do newer studies provide proof in this respect. This is the result of a report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 11 January 2011.

12 Jan 2011

Negative aspects of prostate cancer screening acceptable

The negative aspects of screening for prostate cancer may be acceptable, since screening halves mortality from the disease. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

12 Jan 2011

Behavioral therapies help improve bladder control in men following prostate cancer surgery

Behavioral therapies such as pelvic-floor-muscle training and bladder-control strategies can reduce incontinence episodes by more than 50 percent in men following prostate-cancer surgery, according to new research from the Center for Aging at the University of Alabama at Birmingham and the Birmingham/Atlanta Veterans Affairs Geriatric Research, Education and Clinical Center.

12 Jan 2011

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder.

11 Jan 2011

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

In anticipation of presenting at the JP Morgan Healthcare Conference on January 11, 2011, American Medical Systems Holdings, Inc. reported today preliminary sales of $147.0 million for the fourth quarter of 2010, a 0.7 percent increase over sales of $146.0 million in the comparable quarter of 2009.

11 Jan 2011

Pros and cons of weight loss surgery in men and women

Women who underwent gastric band surgery to lose weight reported significant improvements in urinary function and quality of life after the operation, according to research published in the January issue of the urology journal BJUI.

6 Jan 2011

Ventrus closes public offering of common stock

Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it closed its previously announced public offering of 2,900,000 shares of common stock.

23 Dec 2010

Antares Pharma submits NDA for Anturol Gel in patients with overactive bladder

Antares Pharma, today announced the filing of a New Drug Application with the U.S. Food and Drug Administration for Anturol Gel in patients with overactive bladder.

22 Dec 2010

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

Women suffering from uterine fibroids, a debilitating condition that affects more than seven million women in the U.S., may soon have reason for hope. Halt Medical, a biomedical company based in the San Francisco Bay Area, is developing a minimally invasive procedure for treating the condition. The company recently presented their findings from studies in Latin America at the NIH Global Fibroid Congress.

21 Dec 2010

NAFC forms council to establish independent quality standards for incontinence products

The National Association For Continence (NAFC) is heading a newly formed council with the objective of establishing national, independent quality standards for disposable adult absorbent products provided by states to Medicaid waiver recipients cared for in their private homes rather than as residents of a state-funded nursing home.

20 Dec 2010

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Recordati and Nymox Pharmaceutical Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).

17 Dec 2010

Ventrus prices initial public offering at $6.00 per share

Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol "VTUS". In addition, Ventrus has granted the underwriters a 45-day option to purchase up to an additional 435,000 shares to cover over-allotments, if any.

17 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010

Incontinence News and Research

Latest Incontinence News and Research

New report identifies top research priorities related to Female Pelvic Medicine, Reconstructive Surgery

Invacare 2010 adjusted earnings per share increase 16% to $1.84

Metamark announces Nature journal published landmark prostate cancer study results

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Public services supporting California's low-income, disabled elderly is fragile, says study

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

AMS introduces STEP toolkit to help men with ED and SUI

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

Negative aspects of prostate cancer screening acceptable

Behavioral therapies help improve bladder control in men following prostate cancer surgery

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

Pros and cons of weight loss surgery in men and women

Ventrus closes public offering of common stock

Antares Pharma submits NDA for Anturol Gel in patients with overactive bladder

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

NAFC forms council to establish independent quality standards for incontinence products

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Ventrus prices initial public offering at $6.00 per share

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Incontinence News and Research

Latest Incontinence News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in